FDA Approves Novocure’s Optune Lua® for the Treatment of …
3 days ago · ROOT, Switzerland, October 15, 2024--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 ...
Novocure Press Releases | Latest NVCR News
5 days ago · Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy.
Novocure wins FDA approval for electric field device in lung cancer
18 hours ago · Novocure shares rose 22% from Tuesday afternoon to Wednesday’s market open, before settling down to trade up around 5% by mid-morning. Dive Insight: Novocure’s device first won FDA approval in 2011 in glioblastoma, a rapid and usually deadly type of brain cancer, and then scored another nod in 2019 for the lung cancer mesothelioma.
Novocure's Optune Lua Receives FDA Approval For Lung Cancer …
1 day ago · Novocure (NASDAQ:NVCR), a company focused on developing new treatments for solid tumors, on Oct. 16 announced that the U.S. based FDA has approved their Optune Lua device for NSCLC metastatic ...
NovoCure scoops FDA approval on wearable for metastatic …
2 days ago · NVCR. NovoCure’s Optune Lua, a wearable indicated for use alongside PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel in adult patients with metastatic non-small cell lung cancer (mNSCLC), has ...
Novocure gets FDA approval for its lung cancer treatment - MSN
Novocure (NASDAQ:NVCR) shares rose 6% after market on announcing U.S. FDA approval for Optune Lua for the treatment of adult patients with metastatic non-small cell lung cancer who have progressed ...
Novocure wins FDA nod for lung cancer treatment wearable
1 day ago · October 17, 2024 By Sean Whooley. Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung cancer. Optune Lua uses tumor ...
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, …
3 days ago · H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of $30.00. Emily Bodnar’s rating is based on NovoCure’s ...
Novocure Announces Pivotal LUNAR Study in Non-Small Cell …
Jan 5, 2023 · The LUNAR study is a pivotal, open-label, randomized study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) together with standard therapies for stage 4 non-small cell lung cancer (NSCLC) following progression while on …
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of …
Apr 13, 2021 · HELIER, Jersey– (BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in stage 4 non-small cell lung cancer (NSCLC) following platinum failure.